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Lupus nephritis affects up to 70% of patients with systemic lupus erythematosus and is a major cause of morbidity and mortality.
It is characterized by a breakdown of immune tolerance, production of autoantibodies, and deposition of immune complexes
within the kidney parenchyma, resulting in local inflammation and subsequent organ damage. To date, numerous mediators
of inflammation have been implicated in the development and progression of lupus nephritis, and these include cytokines,
chemokines, and glycosaminoglycans. Of these, type I interferons (IFNs) can increase both gene and protein expression of cytokines
and chemokines associated with lupus susceptibility, and interleukin-6 (IL-6), tumor necrosis factor-𝛼 (TNF-𝛼) and hyaluronan
have been shown to elicit both pro- and anti-inflammatory effects on infiltrating and resident renal cells depending on the status of
their microenvironment. Expression of IL-6, TNF-𝛼, type I IFNs, and hyaluronan are increased in the kidneys of patients and mice
with active lupus nephritis and have been shown to contribute to disease pathogenesis. There is also evidence that despite clinical
remission, ongoing inflammatory processes may occur within the glomerular and tubulointerstitial compartments of the kidney,
which further promote kidney injury. In this review, we provide an overview of the synthesis and putative roles of IL-6, TNF-𝛼,
IFN-𝛼, and hyaluronan in the pathogenesis of lupus nephritis focusing on their effects on human mesangial cells and proximal
renal tubular epithelial cells.
1. Introduction
Renal involvement (i.e. lupus nephritis) is a serious mani-
festation of systemic lupus erythematosus (SLE) that affects
up to 70% of SLE patients and is a strong predictor of
morbidity and mortality [1]. Depending on the severity of
disease, up to 30% of lupus patients will progress to end-stage
renal disease and will require dialysis to sustain life. Lupus
nephritis is prevalent in non-Caucasian females especially
those of child-bearing age and is characterized by a loss of
immune tolerance, production of autoantibodies against nuc-
lear antigens and immune-mediated kidney injury [1]. It is
initiated by the deposition of immune complexes within the
renal parenchyma leading to complement activation, mesan-
gial expansion and induction of inflammatory and fibrotic
processes, resulting in glomerulonephritis and progressive
renal dysfunction.
There is evidence to suggest that anti-dsDNA antibodies
contribute to the pathogenesis of lupus nephritis since many
features of this disease can be reproduced in nonautoimmune
mice after intraperitoneal administration of anti-dsDNA
antibodies [2]. Anti-dsDNA antibodies are also essential
to the diagnosis of SLE, and their levels correlate with
disease activity [3, 4]. We and others have demonstrated
that anti-dsDNA antibodies can bind to mesangial cells,
endothelial cells, and proximal renal tubular epithelial cells
to induce cell proliferation, apoptosis, and inflammatory and
fibrotic processes [5–14]. The precise mechanisms through
which anti-dsDNA antibodies are deposited in the renal
parenchyma remain to be defined, but studies suggest that
they can bind directly to cross-reactive antigens such as
annexin II and 𝛼-actinin on the surface of mesangial cells or
through nucleosomes bound to components of the glomeru-
lar basement membrane, where they induce downstream
inflammatory processes [10, 15–17]. Histologically, glomeru-
lar lesions may range from no or mild mesangial prolifera-
tion to highly proliferative and crescentic glomerulonephri-
tis, whereas tubulointerstitial lesions correlate with renal
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Table 1: Mediators of inflammation that play important roles in the
pathogenesis of lupus nephritis.
Inflammatory
mediator Putative roles in lupus nephritis
IL-6 (i) Activates B cells
(ii) Induces glomerulonephritis
IFN-𝛼 (i) Interferes with vascular repair by inducing
endothelial progenitor cell apoptosis
(ii) Induces renal dysfunction,
glomerulonephritis, crescent formation, and
tubulointerstitial nephritis
IFN-𝛾 Promotes macrophage recruitment into the
kidney and the development of
glomerulonephritis
TNF-𝛼 (i) Regulates physiological and inflammatory
immune responses
(ii) Induces synthesis of IL-1𝛽 and IL-6 in
mesangial cells and proximal renal tubular
epithelial cells
(iii) Elicits both proinflammatory and
anti-inflammatory actions in lupus nephritis
Hyaluronan
(HA)
(i) Forms HA cables that can prevent leukocyte
adhesion to their receptors
(ii) Induces chemokine secretion
(iii) Possesses proinflammatory and
anti-inflammatory properties
prognosis. Serum levels of IL-6, TNF-𝛼, IFN-𝛼, and hyaluro-
nan (HA) are increased in patients with lupus nephritis
[7, 18, 19]. There is accumulating evidence to demonstrate
that their expression is increased in the renal parenchyma
of patients and mice with active lupus nephritis, mediated
in part through stimulation of resident renal cells with anti-
dsDNA antibodies, which contribute to the development
and progression of disease (Table 1) [7, 20–25]. Furthermore,
their synthesis precedes inflammatory cell infiltration and
renal injury. Mesangial cells are an important source of
these inflammatory mediators during the early stage of lupus
nephritis, but as disease progresses, infiltrating lymphocytes,
macrophages, endothelial cells, and proximal renal tubular
epithelial cells are activated by IL-6, TNF-𝛼, IFN-𝛼, and HA,
which further drive the inflammatory processes in the kidney
and highlight their prominent roles in the pathogenesis of
lupus nephritis.This reviewwill discuss the contributing roles
of these inflammatory mediators and their synthesis in the
pathogenesis of lupus nephritis, with particular focus on their
effects inmesangial cells and proximal renal tubular epithelial
cells. The contribution of lymphocytes and macrophages in
amplifying inflammatory processes during lupus nephritis
is outside the scope of this review and has been described
elsewhere [26–29].
2. Interleukin-6 (IL-6)
IL-6 is a pleiotropic cytokine with an MW of 21 kDa that
is secreted by both lymphoid and nonlymphoid cells such
as B cells, T cells, monocytes, mesangial cells, proximal
renal tubular epithelial cells, endothelial cells, and fibroblasts
[10, 30–36]. It is a multifunctional cytokine essential for
the differentiation and maturation of B cells, acute-phase
protein production, and mesangial cell proliferation. IL-6
can target IFN-inducible genes such as Ifi202 in murine
fibroblasts and splenocytes through activation of STAT3,
which results in the suppression of cell cycle progression
and inhibition of apoptosis, thereby contributing to increased
lupus susceptibility [22]. Serum and urinary IL-6 levels are
increased in patients with lupus nephritis, especially in those
with diffuse proliferative lupus nephritis, and correlate with
nephritic flares [37]. In the normal kidney, IL-6 is localized
to the mesangial area and within vascular walls. In patients
with lupus nephritis, its expression is increased in mesangial
cells, induced in podocytes, and is present in glomerular
immune deposits and along the apical aspects of proximal
renal tubular epithelial cells [20, 24, 33, 38].
The mechanisms through which IL-6 is locally produced
in the kidney during pathogenesis of lupus nephritis have
not been fully defined. We have recently demonstrated that
human polyclonal anti-dsDNA antibodies bind to annexin II
on the surface of human mesangial cells and are rapidly inte-
rnalized to induce downstream inflammatory processes
including increased transcription and translation of IL-6,
mediated through increased activation of ERK and p38
MAPK [10]. We have also demonstrated that following bind-
ing and internalization, the subsequent cellular localization
of anti-dsDNA antibodies can influence the amount of IL-6
secreted by mesangial cells. In this respect, induction of IL-
6 secretion is more prominent in cells stimulated with anti-
dsDNA antibodies with intranuclear localization compared
to antibodies that are localized solely to the cytoplasm, and
thismechanism of IL-6 induction occurs with autoantibodies
derived from patients in remission and with relapse [10]. The
importance of anti-dsDNA antibody-annexin II interaction
in the induction of IL-6 secretion was corroborated in
annexin II gene silencing studies [10]. Induction of IL-6
secretion by anti-dsDNA antibodies has also been observed
in ratmesangial cells although themechanism throughwhich
IL-6 was increased was not further investigated [39].
The severity of tubulointerstitial lesions is strongly associ-
ated with less favorable renal prognosis [40]. Although it was
previously believed that glomerular injury provoked tubu-
lointerstitial damage, there is compelling evidence to demon-
strate that proximal renal tubular epithelial cells can directly
contribute to the pathogenesis of lupus nephritis. Up to 70%
of patients with lupus nephritis have discernible immune
aggregates and IL-6 expression along the tubular basement
membrane [33]. Tubulointerstitial expression of IL-6 corre-
lates with IgG deposition, circulating levels of anti-dsDNA
antibodies and tubular abnormalities such as inflammatory
cell infiltration, tubular atrophy, and interstitial fibrosis
in patients with diffuse proliferative lupus nephritis [33].
Proximal renal tubular epithelial cells constitute the pre-
dominant cell type in the tubulointerstitium and play a
pivotal role in the immunopathogenesis of various renal
parenchymal diseases, acting as an effector of immune-
mediated inflammation. Exposure of HK-2 cells, an immor-
talized proximal renal tubular epithelial cell line [41], with
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anti-dsDNA antibodies induced de novo synthesis of both
gene and protein expression of IL-6 [33]. Depending on
the disease status, induction of IL-6 secretion in these cells
was mediated through distinct mechanisms. We demon-
strated that during remission, induction of IL-6 secretion
was mediated through the direct actions of anti-dsDNA
antibodies or indirectly though the prior stimulation of
IL-1𝛽. In contrast, anti-dsDNA antibodies isolated from
the same cohort of patients during relapse increased IL-6
secretion through prior induction of both IL-1𝛽 and TNF-
𝛼 secretion, suggesting autoantibody heterogeneity within
the same patient during remission and relapse [33]. The
ability of anti-dsDNA antibodies obtained from remission
patients to induce cytokine production in renal cells in most
interesting since it would suggest persistence inflammation,
albeit at a lower level to that observed during flare, within
the glomerular and tubulointerstitial compartments of the
kidney despite clinical quiescence. Given that autoreactive
mature na¨ıve B cells are detected in lupus patients during
remission, which are precursors of antibody secreting plasma
cells [42], it is plausible to suggest that this lymphocyte subset
may contribute to persistent autoantibody production and
inflammatory processes within the tubulointerstitium during
the inactive phase of disease.
Inflammatory processes within the glomerular and tubu-
lointerstitial compartments do not occur in isolation. We
have demonstrated that mediators secreted by human mes-
angial cells and HK-2 cells upon stimulation with anti-
dsDNA antibodies can induce IL-6 secretion in the other
cell type, suggesting bidirectional communication between
the glomerulus and tubulointerstitium. Furthermore, at an
identical anti-dsDNA IgG concentration, HK-2 cells demo-
nstrated a more prominent induction of IL-6 secretion com-
pared tomesangial cells, thereby highlighting the importance
of proximal renal tubular epithelial cells in the immu-
nopathogenesis of lupus nephritis [33]. Consistent with our
findings, immunoglobulins of the IgG subclass isolated from
the sera of SLE patients induced IL-6 secretion in proximal
renal tubular epithelial cells, which was accompanied by ERK
activation [43].
Mycophenolic acid (MPA) is the active metabolite of
mycophenolate mofetil [44], an immunosuppressive agent
used in the treatment of patients with lupus nephritis [45–
47]. MPA is a specific inhibitor of lymphocyte prolifera-
tion that noncompetitively inhibits inosine monophosphate
dehydrogenase, a rate-limiting enzyme that plays a critical
role in the de novo synthesis of guanosine nucleotides [44].
There is also accumulating evidence to demonstrate that
MPA can have a direct effect on non-lymphoid cells and has
been shown to inhibit cell proliferation and inflammatory
processes in endothelial cells, smooth muscles cells, tubular
epithelial cells, fibroblasts, and mesangial cells [9, 48–52].
MPA can suppress matrix protein synthesis in mesangial
cells stimulated with exogenous TGF-𝛽1 or anti-dsDNA
antibodies [9, 53]. We have demonstrated that MPA can
suppress anti-dsDNA antibody induction of IL-6 secretion
in HK-2 cells, which was accompanied by a reduction
in cell proliferation [Ng, Yung and Chan, unpublished
data].
The importance of IL-6 in the pathogenesis of lupus
nephritis has been highlighted by independent researchers
who demonstrated that IL-6 can exacerbate glomeru-
lonephritis and disease manifestations in NZB/W mice,
whereas interruption of IL-6 signaling is associated with
reduced circulating anti-dsDNA antibody levels, improved
renal histology and function, decreased proteinuria, and
increased survival in lupus-prone mice [21, 54–57]. Whether
disease progression in patients with lupus nephritis can be
suppressed by targeting IL-6 remains to be determined.
3. Tumour Necrosis Factor-𝛼 (TNF-𝛼)
TNF-𝛼 is a prototype proinflammatory cytokine that is
predominantly synthesized by activated macrophages and
lymphocytes, and to a lesser extent by intrinsic renal cells. It
is synthesized as a 26 kDa membrane-bound protein that is
activated and released as a 17 kDa soluble cytokine by TNF-
𝛼-converting enzymes belonging to the ADAM (a disintegrin
and metalloproteinase) family [58]. Low levels of TNF-
𝛼 mRNA can be detected in lupus-prone mice prior to
renal injury [59]. Renal expression and circulating levels of
bioactive TNF-𝛼 are increased during clinical and experi-
mental lupus nephritis and correlate with disease activity
[19, 24, 60, 61]. We have previously demonstrated that the
induction of TNF-𝛼 secretion by anti-dsDNA antibodies
in mesangial cells and proximal renal tubular epithelial
cells was an early event and contributed to increased IL-
6 secretion [7, 33]. We further demonstrated that TNF-𝛼
can act synergistically with anti-dsDNA antibodies obtained
from patients with active disease to amplify inflammatory
responses, an observation not noted with autoantibodies iso-
lated from patients in remission. Increased TNF-𝛼 secretion
can induce apoptotic cell death in resident renal cells, a
mechanism that may initiate organ-specific damage. TNF-𝛼
may also exert distinct effects on the kidney depending on
the immunologic microenvironment during different stages
of disease. Administration of TNF-𝛼 to predisease NZB/W
mice delayed the onset of disease, whereas administration
of low, but not high, doses of TNF-𝛼 to lupus-prone mice
with active disease exacerbated renal injury [62]. In order to
induce renal damage, researchers have suggested that TNF-
𝛼 interacts with pathologic mediators present either locally
or in the circulation that are not synthesized in pre-disease
lupus-prone mice. Notable, these pathologic mediators have
yet to be identified. Higher doses of TNF-𝛼 may exert a
protective effect through the induction of tolerance [62]. In
support of this hypothesis, Wallach et al. demonstrated that
administration of sublethal doses of TNF-𝛼 to BALB/c mice
resulted in tolerance following TNF-𝛼 rechallenge [63]. The
beneficial role of TNF-𝛼 in the pathogenesis of disease is
substantiated by findings that decreased synthesis of TNF-
𝛼 in NZB/W mice is associated with the development of
lupus nephritis [64]. In contrast to these findings, increased
intrarenal TNF-𝛼 expression in NZB/W or MRL/lpr mice
correlated with renal inflammation and disease activity, a
finding not observed in their congenic littermate [59, 62]. It is
possible that genetic predisposition may regulate the effect of
TNF-𝛼 in the pathogenesis of lupus nephritis. So, how should
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one conclude whether induction of TNF-𝛼 secretion by
anti-dsDNA antibodies in resident renal cells is detrimental
or protective? Given that anti-dsDNA antibody-mediated
induction of TNF-𝛼 increased IL-1𝛽 and IL-6 secretions in
mesangial and proximal renal tubular epithelial cells, it is
plausible to suggest that under these experimental settings,
TNF-𝛼 exerts a pro-inflammatory effect in the kidney. Induc-
tion of TNF-𝛼 expression in the kidney and cultured proximal
renal tubular epithelial cells ismediated in part, through prior
activation of p38 MAPK during progressive lupus nephritis
[65].
Since TNF-𝛼 exerts dual effects on resident renal cells,
administration of agents to block TNF-𝛼 in SLE patients
should be approached with caution. Furthermore, their effe-
ctiveness in suppressing disease manifestations remains
debatable. Aringer et al. reported that the treatment of pati-
ents with lupus nephritis with infliximab, a monoclonal
antibody against TNF-𝛼, for up to 10 weeks improved pro-
teinuria but also transiently increased anti-dsDNA antibody
production, a result of increased apoptotic bodies and thus
autoantigens following TNF-𝛼 depletion [66, 67]. Longer
treatment with infliximab was associated with adverse side
effects that included fatal pneumonia and brain lymphoma
although whether this was attributed to the use of infliximab
or prior use of other immunosuppressive agents remains to be
determined [66]. In patientswith rheumatoid arthritis receiv-
ing anti-TNF-𝛼 therapy, side effects encountered included
the development of drug-induced lupus-like syndromes, anti-
dsDNA antibody production, and glomerulonephritis [68–
70]. How can TNF-𝛼 mediate disease development? Exper-
imental studies have suggested that TNF-𝛼 can inhibit type I
IFN, a family of pro-inflammatory cytokines known to exert
pathogenic roles in the development of lupus nephritis.When
TNF-𝛼 is inhibited by anti-TNF agents, synthesis of type I IFN
is no longer repressed, thereby permitting the exacerbation
of inflammatory processes. Whether similar findings are
observed in lupus patients remain to be determined. The
actions of TNF-𝛼 in the pathogenesis of lupus nephritis have
also been confounded by reports that anti-TNF-𝛼 treatment
inNZB/Wmicewith active lupus nephritis induced by IFN-𝛼
protected the mice against renal damage and prolonged their
survival by attenuating the kidney’s response to glomerular
immune complex deposition [71]. Blockade of TNF-𝛼 activity
in patients or animals with lupus nephritis may be beneficial
or otherwise depending on the dose, treatment duration, and
status of disease when treatment is administered. Is it possible
to suppress the pro-inflammatory properties of TNF-𝛼, while
retaining its anti-inflammatory properties?
4. Type I Interferons (IFNs)
The type I IFN family consists of IFN-𝛼, IFN-𝛽, IFN-𝜔,
IFN-𝜅, and IFN-𝜀.These pleiotropic cytokines are key regula-
tors of the innate and adaptive immunity, and their levels are
increased during antiviral responses and autoimmune dise-
ases [72]. Type I IFNs can promote cell proliferation and dif-
ferentiation of monocytes and B cells into antigen-presenting
cells or plasma cells, respectively. These cytokines mediate
their inflammatory responses through their engagement with
a common heterodimeric receptor composed of type I IFN
receptor 1 and 2 subunits. There is evidence that IFN-𝛼
plays a critical role in the development of lupus nephritis.
Serum levels of IFN-𝛼 and its expression in the glomeruli of
lupus patients correlate with disease activity [73–76]. Studies
have suggested that increased serum IFN-𝛼 bioactivity and
polymorphism of interferon regulatory factor 5 gene, a
transcription factor essential for IFN-𝛼 secretion, are associ-
ated with SLE and lupus nephritis susceptibility, respectively
[77, 78]. Patients with viral infections or malignant tumors
frequently develop SLE-like manifestations and anti-DNA
antibodies following IFN-𝛼 treatment, thereby corroborating
the importance of this cytokine in the development of
lupus [79–81]. Although plasmacytoid dendritic cells are the
primary source of type I IFNs in lupus patients, intrinsic
renal cells such as mesangial cells and glomerular endothelial
cells can also synthesize IFN-𝛼 following stimulation with
viral components mediated through toll-like receptor depen-
dent and independent pathways [82–84]. Synthesis of IFN-
𝛼 by endothelial cells may contribute to the infiltration of
inflammatory cells into the kidney parenchyma. Stimulation
of mesangial and proximal renal tubular epithelial cells with
anti-dsDNA does not induce IFN-𝛼 secretion (Yung and
Chan, unpublished observation). Fairhurst et al. demon-
strated that type I IFNs synthesized by resident renal cells
in an experimental model of anti-GBM nephritis induced
renal dysfunction, glomerulonephritis, crescent formation,
and tubulointerstitial nephritis [85].
Exposure of NZB/W mice to IFN-𝛼 can accelerate
pathogenic autoantibody production, proteinuria develop-
ment, and glomerular IgG deposition and render these mice
more resistantly to therapeutic intervention when compared
to lupus-prone mice without IFN-𝛼 treatment [23, 86, 87].
Gene silencing of IFN-𝛼/𝛽R in NZB mice, which ablated
the biological activities of IFN-𝛼/𝛽, suppressed splenomegaly,
anti-dsDNA antibody production, and kidney pathology and
improved survival compared to their wildtype littermates,
thereby substantiating the pathogenic role of type I IFN in
promoting SLE [88].
IFN-induced mRNA transcripts, otherwise known as
IFN-signature, are increased in peripheral blood mononu-
clear cells isolated from SLE patients and may serve as a
marker for more severe organ manifestations such as lupus
nephritis [89, 90]. Increased IFN-𝛼-inducible transcripts
have been observed in the glomeruli of patients with lupus
nephritis, which inversely correlated with many genes that
promote renal fibrosis [91]. Intriguingly, this would suggest
that the expression of IFN-inducible transcripts could either
result in a milder form of renal injury or be protective
against glomerular damage [91].Whether the presence of this
signature is a cause or consequence of disease remains to be
fully defined.
5. Hyaluronan (HA)
HA is a large, negatively-charged, nonsulfated glycosamino-
glycan composed of repeating disaccharide units of D-
glucuronic acid and N-acetyl-D-glucosamine [92]. It is syn-
thesized on the inner surface of the plasma membrane by
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HA synthases (HAS), and newly synthesized HA is either
directed to the cell surface where it interacts with its receptor
CD44 or is assembled into the extracellular matrix. Three
HAS isoenzymes have been identified that share 55–70%
homology and are termed HAS I, HAS II, and HAS III [93].
Under physiologic conditions, HA may possess up to 25,000
disaccharide units with a corresponding molecular mass of
106–107Da [94]. HA contributes to basement membrane
stability and sequestration of free radicals and plays critical
roles in cell proliferation, differentiation, migration, and
phenotypic changes.
In the normal kidney, HA is primarily expressed within
the inner medulla interstitium where it contributes to the
mechanical stability of tubules and blood vessels, and also
in the concentration of urine [95]. In patients and mice
with active lupus nephritis, HA expression extends into the
renal cortex and has a periglomerular, crescentic, mesangial,
and tubulointerstitial distribution [7, 96, 97]. We and others
have demonstrated that cultured mesangial cells, glomerular
endothelial cells, proximal renal tubular epithelial cells, and
interstitial fibroblasts can synthesize HA [7, 98–103], and it
is thus plausible to suggest that these cell types contribute
to increased HA levels in the renal cortex in lupus patients.
HA accumulation in the tubulointerstitium correlates with
lymphocyte infiltration and renal damage mediated in part,
through prior induction of TNF-𝛼 and IFN-𝛾 [97]. There
is mounting evidence to suggest that during chronic kidney
inflammation, mesangial cells and proximal renal tubular
epithelial cells synthesize HA that forms long cable-like
structures that function as an adhesive matrix, which binds
leukocytes and macrophages preventing them from interact-
ingwith adhesionmolecules, thereby limiting glomerular and
tubulointerstitial inflammation [104–106].
Human polyclonal anti-dsDNA antibodies can increase
high molecular weight (HMW) HA synthesis and induce
synthesis of low molecular weight (LMW) HA in mesangial
and proximal renal tubular epithelial cells when compared
to control cells, mediated in part through prior induction
of IL-1𝛽 secretion, and increased HAS II gene expression
[7, 107]. Independent researchers have demonstrated that
the biological functions of HA is governed by its molecular
weight. HMW HA possesses anti-inflammatory and antian-
giogenic properties and can promote cell quiescence, whereas
LMW HA is pro-inflammatory and can induce cytokine
and chemokine secretion, activation of signalling pathways,
cell proliferation, and angiogenesis [108–113]. The presence
of LMW HA can arise through de novo synthesis during
inflammation or through the depolymerisation of native HA
following increased hyaluronidase activity or exposure to
reactive oxygen species [110]. Pro-inflammatory cytokines
can increase synthesis of both HMW and LMW HA in
various cell types. Although we and others have shown an
increase in intrarenal HA expression in patients and mice
with active lupus nephritis, its MW was not investigated
[7, 97, 114]. It is noteworthy that despite differences in
the biological functions of HMW and LMW HA, reports
detailing the presence of LMW HA in tissues undergoing
inflammation and injury are scarce.
Exogenous LMW, but not HMW HA, can induce MCP-
1 mRNA and protein secretion in proximal renal tubular
epithelial cells [25]. Glomerular and tubulointerstitial expres-
sion of MCP-1 is increased in lupus-prone mice and precedes
leukocyte infiltration, proteinuria, and renal damage [115].
The significance of MCP-1 in the pathogenesis of lupus
nephritis was highlighted by Tesch et al. who observed that
MRL/lpr mice deficient in MCP-1 demonstrated increased
survival consequent to less severe renal histology and pro-
teinuria compared to their wildtype littermates [116].We have
demonstrated that suppression ofHA synthesis inNZBWF1/J
mice was associated with an improvement in clinical param-
eters of disease and decreased intrarenal expression of IL-6
and TNF-𝛼 [96]. It would be most interesting to determine
whether HA is a potential target for therapeutic intervention
in the pathogenesis of lupus nephritis.
Serum HA levels are increased in patients with lupus
nephritis compared to healthy controls and correlate with
circulating anti-dsDNA antibody levels, suggesting that these
autoantibodies contribute to increased HA synthesis [7]. It
is noteworthy that an increase in the level of circulating HA
is not specific to lupus but rather, a consequent of renal
impairment and injury [117–119]. Elevated serum HA levels
are associated with inflammation, malnutrition, and poor
prognosis in patients with end-stage renal failure [120].
6. Conclusions
Although a plethora of inflammatory mediators have been
implicated in the development and pathogenesis of lupus
nephritis, our understanding of how they mediate renal
injury has been confounded by their multifunctional roles.
There is compelling evidence to demonstrate that resident
renal cells can directly contribute to renal inflammation
through their ability to secrete cytokines, chemokines, and
glycosaminoglycans following their interaction with, but not
limited to, anti-dsDNA antibodies and viral components.
Disease remission and prevention of irreversible renal
damage are the ultimate goals of induction therapy but
irrespective of achieving clinical remission, studies have
demonstrated that low-grade inflammatory processes may
persist within the renal parenchyma leading to further kidney
injury. Further research into the mechanisms through which
pro-inflammatory mediators are modulated during disease
manifestations, how they interact with other inflammatory
mediators, and the underlying mechanisms that dictate
whether these molecules elicits pro- or anti-inflammatory
responses will provide us with a better understanding of
their roles in lupus nephritis and whether targeting these
molecules can improve clinical outcome without affecting
their physiological roles.
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